Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (3802)	5/15/2001 11:15:15 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

The new NIH guidelines for cholesterol should mostly benefit the statin purveyors, which are currently all pharmas. However, one biotech, KOSP, should benefit. Currently if you want to raise HDL, then KOSP's drug is the only game in town. This will likely change in a few years as all the pharmas are charging very hard after an effective drug, but meantime KOSP should benefit. Their new drug, a combined lovastatin (generic version) and niacin should also do nicely once it is approved, particularly in a cost-conscious environment. Here's a CNN write-up of the new guidlines: cnn.com Peter